Mei Wang China

biotech focusing on world leading r&d to solve unmet medical needs
Partnering Objectives
Headquartner in China
Biotech/Pharma Category
dizal pharmaceutical
team leader 

Yuhuan Wang Singapore

iX Biopharma is established in 2008, and listed on Singapore Stock Exchange (Catalist Board) in 2015. iX is a specialist in novel wafer formulations using patented sublingual delivery technology, WaferiXTM , which is patented in China to 2033. R&D and manufacturing at wholly-owned GMP licensed facility in Melbourne, Australia.
Company Size (Fulltime employees)
Year of foundation
2008
Please specify your partnering goal
(1) Licensing Partner (2) Sublingual wafer development technology collaboration
Headquartner in China
Biotech/Pharma Category
Biotech/Pharma Asset Stage
iX Biopharma Ltd
Senior BD Manager 
Functionality

Renfei WANG United States

Website:
www.huyabio.com
Partnering Objectives
Please specify your partnering goal
To find new projects of interest
Headquartner in China
HUYA BIOSCIENCE INTERNATIONAL
Scientific liaison manager 

grace wang China

DENTAL MATERIALS
STENTS
EPIDEMIC PREVENTION PRODUCTS ETC.
Website:
www.atmbio.com
Partnering Objectives
Headquartner in China
Beijing ATMbiomaterials Co., Ltd
MD 

Dr Yinxiang Wang China

Company Size (Fulltime employees)
Year of foundation
5
Biotech/Pharma Category
Jacobio Pharmaceuticals
Chairman and CEO 
Functionality

Miss Chara Wang China

Big Pharma
Website:
sanofi
Company Size (Fulltime employees)
Please specify your partnering goal
understand the mkt
Headquartner in China
Biotech/Pharma Category
Sanofi
FBP 
Functionality

Dr. Tianke Wang Switzerland

Dao Tun is a consulting company, founded in 2019, specialised in cross-border collaboration between Europe and China, primarily in the healthcare and life science industry.
Dao Tun is based in the Basel region, one of the world's leading clusters for Pharma and Life Sciences and also part of the trinational Biovalley region (Switzerland, Germany, France).
Dao Tun team provides customised strategy and execution plan via in-depth interview and targeted research; quickly gains insights into the association and matching between potential partners to make accurate and effective connections; simplifies the processes, reduces the cost of communication, and establishes the trust with full care.
Dao Tun is a bridge builder who excels at understanding and interpreting their interests and needs, and aligning perspectives of different stakeholders and across cultures for win-win-win situation.

Dr. Tianke Wang
Dao Tun GmbH
CEO 
Functionality

Mr. Jason Wang United States

Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is advancing the clinical development of its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of patients with wet age-related macular degeneration and diabetic macular edema. For more information, please visit www.adverum.com.
Website:
adverum.com
Company Size (Fulltime employees)
Partnering Objectives
Please specify your partnering goal
N/A
Headquartner in China
Adverum Biotechnologies
Associate Director Strategy 

William Wang China

Pls check us at company website.
Partnering Objectives
Headquartner in China
Tianda Pharmaceutical Ltd
EVP 

Ying Wang China

Pharma and diagnostics
Website:
Roche.com
Headquartner in China
Roche
BD director